DK3307323T3 - Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf - Google Patents

Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf Download PDF

Info

Publication number
DK3307323T3
DK3307323T3 DK16738883.4T DK16738883T DK3307323T3 DK 3307323 T3 DK3307323 T3 DK 3307323T3 DK 16738883 T DK16738883 T DK 16738883T DK 3307323 T3 DK3307323 T3 DK 3307323T3
Authority
DK
Denmark
Prior art keywords
treatment
conditions
related symptoms
fibrotic diseases
carbazole derivatives
Prior art date
Application number
DK16738883.4T
Other languages
English (en)
Inventor
Shmuel Ben-Sasson
Original Assignee
Raziel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raziel Therapeutics Ltd filed Critical Raziel Therapeutics Ltd
Application granted granted Critical
Publication of DK3307323T3 publication Critical patent/DK3307323T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
DK16738883.4T 2015-06-15 2016-06-14 Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf DK3307323T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175552P 2015-06-15 2015-06-15
PCT/IL2016/050624 WO2016203468A1 (en) 2015-06-15 2016-06-14 Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Publications (1)

Publication Number Publication Date
DK3307323T3 true DK3307323T3 (da) 2022-08-15

Family

ID=56411840

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16738883.4T DK3307323T3 (da) 2015-06-15 2016-06-14 Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf

Country Status (6)

Country Link
US (3) US10632102B2 (da)
EP (1) EP3307323B1 (da)
DK (1) DK3307323T3 (da)
ES (1) ES2924728T3 (da)
IL (1) IL256329B (da)
WO (1) WO2016203468A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
JP7822308B2 (ja) * 2019-09-15 2026-03-02 ラジエル セラピューティクス エルティーディー. 固形腫瘍の処置のための組成物
EP4096653A4 (en) * 2020-01-28 2024-02-28 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
WO2022234337A2 (en) * 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative
EP4615443A1 (en) * 2022-11-07 2025-09-17 Raziel Therapeutics Ltd. Crystalline carbazole derivative and methods of making thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2590125A (en) 1952-03-25 Quaternary-ammonium alkyl
US2676966A (en) 1951-04-04 1954-04-27 Searle & Co Quaternary salts of 9-carbazolealkylamines and 10-acridanalkylamines and methods forpreparing same
US2930798A (en) 1956-08-03 1960-03-29 Clin Byla Ets 3-alkanoyl 1-tertiary-amino-alkyl indol oximes and production thereof
GB832568A (en) 1956-08-03 1960-04-13 Clin Byla Ets Heterocyclic compounds and production thereof
FR1186832A (fr) 1956-08-03 1959-09-02 Etablissements Clin-Byla Composés hétérocycliques dérivés du pyrrol et des benzopyrrols et leur fabrication
US3836587A (en) 1969-11-17 1974-09-17 American Cyanamid Co Organo phosphonium salts
AU5644396A (en) 1995-05-05 1996-11-21 Novo Nordisk A/S Novel heterocyclic chemistry
PL332896A1 (en) 1996-10-30 1999-10-25 Lilly Co Eli Substituted tricyclic compounds
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1094063A1 (en) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
GB9925880D0 (en) 1999-11-01 1999-12-29 British Tech Group Int B-Carboline derivatives
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
WO2003027084A1 (en) 2001-09-25 2003-04-03 Dr. Reddy's Laboratories Ltd. Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents
GB0311406D0 (en) 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
US20070213359A1 (en) 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
US8617543B2 (en) 2007-02-14 2013-12-31 Yolare Pharmaceuticals, LLC Modified mutant collagenase and its use in fat melting and in scar reduction
US20090317372A1 (en) 2008-06-20 2009-12-24 Zoltan Kiss Small molecules for the reduction of high blood glucose level
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
JP5766614B2 (ja) 2009-01-09 2015-08-19 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System 神経新生促進化合物
AU2011274787B2 (en) 2010-07-07 2016-06-16 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
KR101986272B1 (ko) * 2011-11-15 2019-06-05 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
AU2014340351B2 (en) 2013-10-21 2020-01-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016020919A1 (en) 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
JP7822308B2 (ja) 2019-09-15 2026-03-02 ラジエル セラピューティクス エルティーディー. 固形腫瘍の処置のための組成物
EP4096653A4 (en) 2020-01-28 2024-02-28 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
US20240041827A1 (en) 2020-09-16 2024-02-08 Raziel Therapeutics Ltd. Compositions for the treatment of fat related conditions and disorders
EP4213835A4 (en) 2020-09-16 2024-10-02 Raziel Therapeutics Ltd. COMPOSITIONS AND METHODS FOR TREATING LIPID-RELATED DISORDERS
WO2022234337A2 (en) 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative

Also Published As

Publication number Publication date
ES2924728T3 (es) 2022-10-10
IL256329B (en) 2021-04-29
US20200222364A1 (en) 2020-07-16
US20220117935A1 (en) 2022-04-21
US20180169066A1 (en) 2018-06-21
US12097179B2 (en) 2024-09-24
EP3307323A1 (en) 2018-04-18
IL256329A (en) 2018-02-28
EP3307323B1 (en) 2022-07-13
WO2016203468A1 (en) 2016-12-22
US10632102B2 (en) 2020-04-28
US11191748B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3340981T3 (da) Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
LT3169328T (lt) Chinolino dariniai, skirti uždegiminių ligų gydymui
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3294345T3 (da) Tpp1-formuleringer og fremgangsmåder til behandling af cln2-sygdom
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK3157531T3 (da) Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3218351T3 (da) Fremgangsmåde til fremstilling, isolering og oprensning af farmaceutisk anvendelige former af ahu-377
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
DK3722291T3 (da) Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
DK3307323T3 (da) Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf